1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
    Meeting Abstract

    Choueiri, T. K.; Powles, T. B.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Riuz, E. Y.; Maruzzo, M.; Zaizar, A. S.; Fein, L. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
    Meeting Abstract

    Kasper, B.; Ratan, R.; Alcindor, T.; Schoeffski, P.; van Der Graaf, W. T. A.; Wilky, B. A.; Riedel, R. F.; Lim, A.; Smith, L. M.; Moody, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC
    Meeting Abstract

    Strickler, J. H.; Cercek, A.; Siena, S.; Andre, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
    Meeting Abstract

    Aggarwal, R.; Heller, G.; Hillman, D.; Xiao, H.; Picus, J.; Wang, J.; Taplin, M. E.; Dorff, T.; Appleman, L. J.; Weckstein, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E. M.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
    Meeting Abstract

    Klempner, S. J.; Weiss, J.; Pelster, M.; Spira, A.; Barve, M.; Ou, S. H. I.; Leal, A.; Bekaii-Saab, T.; Christensen, J. G.; Kheoh, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
    Meeting Abstract

    Koshkin, V. S.; Powles, T. B.; Iyer, G.; Loriot, Y.; Drakaki, A.; Martinez, I. D.; De Santis, M.; Retz, M.; Jain, R. K.; Chan, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save